Heightened FDA Scrutiny ‘Key Risk’ For Indian Pharma: ICRA
This article was originally published in The Gold Sheet
Executive Summary
FDA warning letters are emerging as an important risk for India's pharmaceutical sector, says leading investment rating agency ICRA, with such notices climbing by 143% in calendar 2015 from the previous year.